Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD8+ cells, gene level]. Homo sapiens

We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment. This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD8+ cells, preprocessed according to the gene level workflow. Overall design: EDTA blood samples were taken from all patients immediately before first and second fingolimod administration as well as after 3 months of therapy. Total RNA of CD8+ cells positively selected from each blood sample was extracted, labeled and hybridized to high-density Affymetrix HTA 2.0 microarrays to quantify the transcript levels.

本研究对复发缓解型多发性硬化（relapsing-remitting multiple sclerosis, RRMS）患者群体在芬戈莫德（fingolimod）治疗前及治疗过程中的不同血细胞类型基因表达模式进行了分析。本研究采用Affymetrix人类转录组芯片（Affymetrix Human Transcriptome Arrays, HTA）2.0平台，获取了10名RRMS患者在芬戈莫德治疗首3个月内的免疫细胞群体基因表达谱。本基因表达综合数据库（Gene Expression Omnibus, GEO）条目收录了外周血CD8+细胞的Affymetrix HTA 2.0微阵列数据，该数据已按照基因水平分析流程完成预处理。实验设计：采集所有患者的乙二胺四乙酸（ethylenediaminetetraacetic acid, EDTA）抗凝全血样本，采样时点分别为首次及第二次芬戈莫德给药前，以及治疗3个月后。从每份血液样本中阳性分选得到的CD8+细胞的总RNA被提取、标记后，与高密度Affymetrix HTA 2.0微阵列进行杂交，以实现转录本水平的定量检测。